Blueprint Medicines (NASDAQ:BPMC) Issues Quarterly Earnings Results, Misses Expectations By $0.11 EPS

Blueprint Medicines (NASDAQ:BPMC) posted its earnings results on Thursday. The biotechnology company reported ($0.79) EPS for the quarter, missing the consensus estimate of ($0.68) by ($0.11), Zacks reports. Blueprint Medicines had a negative net margin of 13.19% and a negative return on equity of 77.49%.

Blueprint Medicines Stock Performance

Shares of Blueprint Medicines stock opened at $92.25 on Friday. The company has a quick ratio of 2.80, a current ratio of 2.85 and a debt-to-equity ratio of 1.15. The stock has a 50 day moving average price of $99.55 and a two-hundred day moving average price of $94.39. Blueprint Medicines has a 12-month low of $80.42 and a 12-month high of $121.90.

Insiders Place Their Bets

In other news, CEO Kate Haviland sold 1,446 shares of the company’s stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $110.24, for a total transaction of $159,407.04. Following the completion of the transaction, the chief executive officer now directly owns 149,378 shares in the company, valued at $16,467,430.72. The trade was a 0.96 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Christina Rossi sold 2,274 shares of the company’s stock in a transaction on Wednesday, November 27th. The shares were sold at an average price of $95.10, for a total value of $216,257.40. Following the completion of the transaction, the chief operating officer now owns 71,657 shares of the company’s stock, valued at $6,814,580.70. The trade was a 3.08 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 49,851 shares of company stock valued at $4,984,696 over the last 90 days. 4.21% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several research firms recently commented on BPMC. Needham & Company LLC restated a “buy” rating and issued a $133.00 target price on shares of Blueprint Medicines in a research report on Thursday, February 13th. Guggenheim reiterated a “buy” rating on shares of Blueprint Medicines in a research report on Wednesday, December 11th. JPMorgan Chase & Co. lifted their price target on Blueprint Medicines from $126.00 to $129.00 and gave the company an “overweight” rating in a research report on Tuesday, February 4th. StockNews.com upgraded Blueprint Medicines from a “sell” rating to a “hold” rating in a report on Saturday. Finally, Wells Fargo & Company decreased their target price on Blueprint Medicines from $153.00 to $151.00 and set an “overweight” rating on the stock in a report on Thursday, October 31st. One analyst has rated the stock with a sell rating, seven have issued a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $123.83.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.